Trexquant Investment LP Buys Shares of 150,022 REGENXBIO Inc. (NASDAQ:RGNX)

Trexquant Investment LP acquired a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 150,022 shares of the biotechnology company's stock, valued at approximately $1,160,000. Trexquant Investment LP owned 0.30% of REGENXBIO at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in RGNX. JPMorgan Chase & Co. increased its position in shares of REGENXBIO by 67.0% during the 4th quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock valued at $31,975,000 after purchasing an additional 1,659,206 shares during the period. Geode Capital Management LLC boosted its position in REGENXBIO by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,094,225 shares of the biotechnology company's stock worth $8,460,000 after acquiring an additional 5,574 shares during the period. Assenagon Asset Management S.A. lifted its position in REGENXBIO by 53.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock worth $6,621,000 after buying an additional 296,700 shares in the last quarter. Norges Bank purchased a new stake in shares of REGENXBIO during the 4th quarter worth about $3,474,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in REGENXBIO by 9.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company's stock valued at $4,382,000 after buying an additional 37,055 shares in the last quarter. 88.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on RGNX shares. Leerink Partners set a $24.00 target price on shares of REGENXBIO in a research note on Tuesday, March 18th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $30.00 price target on shares of REGENXBIO in a research note on Tuesday, January 21st. Morgan Stanley increased their price objective on REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, March 14th. The Goldman Sachs Group lowered shares of REGENXBIO from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $38.00 to $14.00 in a report on Tuesday, February 11th. Finally, HC Wainwright decreased their price objective on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, March 17th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, REGENXBIO has a consensus rating of "Moderate Buy" and an average price target of $31.88.

REGENXBIO Stock Down 5.0 %

NASDAQ RGNX traded down $0.33 on Wednesday, reaching $6.22. The company had a trading volume of 120,537 shares, compared to its average volume of 795,460. The stock has a market cap of $311.73 million, a price-to-earnings ratio of -1.24 and a beta of 1.26. REGENXBIO Inc. has a 52 week low of $5.04 and a 52 week high of $18.24. The stock's 50 day moving average is $6.92 and its 200-day moving average is $8.23.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. The business had revenue of $21.21 million for the quarter, compared to analysts' expectations of $23.70 million. As a group, analysts forecast that REGENXBIO Inc. will post -4.84 EPS for the current year.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.